期刊文献+

利妥昔单抗治疗原发性巨球蛋白血症疗效观察

CLINICAL OBSERVATION ON THE EFFECT OF MABTHERA IN THE TREATMENT OF PRIMARY WALDENSTROM'S MACROGLOBULINEMIA
下载PDF
导出
摘要 目的探讨利妥昔单抗(美罗华)治疗原发性巨球蛋白血症患者的疗效。方法对6例原发性巨球蛋白血症患者给予美罗华375mg/m^2,每周1次,每4周为一疗程,3个月后重复治疗4周。结果 6例中部分缓解3例,病情稳定2例,1例患者因有持续血尿而退出美罗华维持治疗,但血尿在治疗2周后消失。结论美罗华治疗原发性巨球蛋白血症安全有效。 Objective To study the effect of Mabthera in treating primary Waldenstrom′s macroglobulinemia. Methods The patients were treated with Mabthera at the dose of 375mg/m^2/ week. Each course of treatment lasted four weeks, and repeated after 3 months. Results Three patients reached partial remission (PR) ,two patients' condtions were stabilized, and one patient quit treating because of continuous hematuresis , but hematuresis ever vanished after 2 weeks. Conclusion Mabthera was effective and safe in the treatment of primary Waldenstrom′s macroglobulinemia.
出处 《河北医科大学学报》 CAS 2011年第5期519-520,共2页 Journal of Hebei Medical University
关键词 WALDENSTROM巨球蛋白血症 美罗华 治疗结果 Waldenstrom's macroglobulinemia Mabthera treatment outcome
  • 引文网络
  • 相关文献

参考文献5

  • 1TREON SP, BRANAGAN AR, HUNTER ZR, et al. Long time outcomes to fludarabine and rituximabin Macroglobulinemia [ J ]. Blood ,2009,113 (16) :3673 - 3678.
  • 2ANAGNOSTOPOULOS A, GIRALT S. Stem cell transplantation ( SCT ) for Waldenstioms macroglobulinemia [ J ]. Bone Marrow Transplant,2002,29 (12) :943 - 947.
  • 3GHOBRIAL IM, FONSECA R, GRIEPP PR , et al. Initial immunoglobulin M flare after rituximab therpy, in patient " diagnosed with Waldenstrom macroglobulinemia: an Eastern cooperative oncology group study [ J ]. Cancer, 2004, 101 ( 11 ) : 2593 - 2598.
  • 4DIMOPOULOS MA, GERTZ MA, TRENON SP. Update on treatment recommation from the fourth interrational workshop on macroglobulinemia[ J ]. Clinical Oncology, 2009,27 ( 1 ) : 120 - 126.
  • 5GERTZ MA , MERLINI G, TREON SP. Amyloidos is and Waidenstioms macroglobulinemia [ J ]. Hematol AM SocHematol Edue Program,2004,36 ( 8 ) :257 - 282.

相关主题

;
使用帮助 返回顶部